- Home
- CKPT vs NCV Comparison
CKPT vs NCV Comparison
Compare CKPT & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- NCV
- Stock Information
- Founded
- CKPT 2014
- NCV 2003
- Country
- CKPT United States
- NCV United States
- Employees
- CKPT N/A
- NCV N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- CKPT Health Care
- NCV Finance
- Exchange
- CKPT Nasdaq
- NCV Nasdaq
- Market Cap
- CKPT 335.9M
- NCV 274.5M
- IPO Year
- CKPT 2017
- NCV N/A
- Fundamental
- Price
- CKPT $4.17
- NCV $13.31
- Analyst Decision
- CKPT Buy
- NCV
- Analyst Count
- CKPT 3
- NCV 0
- Target Price
- CKPT $4.33
- NCV N/A
- AVG Volume (30 Days)
- CKPT 1.0M
- NCV 405.1K
- Earning Date
- CKPT 05-16-2025
- NCV 01-01-0001
- Dividend Yield
- CKPT N/A
- NCV 12.48%
- EPS Growth
- CKPT N/A
- NCV N/A
- EPS
- CKPT N/A
- NCV N/A
- Revenue
- CKPT $41,000.00
- NCV N/A
- Revenue This Year
- CKPT $102,182.93
- NCV N/A
- Revenue Next Year
- CKPT $351.71
- NCV N/A
- P/E Ratio
- CKPT N/A
- NCV N/A
- Revenue Growth
- CKPT N/A
- NCV N/A
- 52 Week Low
- CKPT $1.47
- NCV $2.84
- 52 Week High
- CKPT $4.50
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- CKPT 71.99
- NCV 61.37
- Support Level
- CKPT $4.02
- NCV $12.93
- Resistance Level
- CKPT $4.17
- NCV $13.39
- Average True Range (ATR)
- CKPT 0.03
- NCV 0.20
- MACD
- CKPT -0.01
- NCV 0.08
- Stochastic Oscillator
- CKPT 93.33
- NCV 92.38
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.